Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melhem Solh

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
NEJM Evidence|February 25, 2025
Haploidentical Bone Marrow Transplantation for Sickle Cell DiseaseAdetola A Kassim, Mark C Walters, Mary Eapen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 15, 2017
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic SyndromesAaron T Gerds, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood Advances|November 7, 2018
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemiaSaurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, et al.
JAMA Oncology|May 6, 2021
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell TransplantMichael Scordo, Trent P Wang, Kwang W Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>Mark J Levis, Mehdi Hamadani, Brent Logan, et al.
Leukemia|June 6, 2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Bone Marrow Transplantation|February 1, 2018
Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantationLucie M Turcotte, Tao Wang, Michael T Hemmer, et al.
Haematologica|April 21, 2022
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysisMatthew Mei, Raju Pillai, Soyoung Kim, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
NEJM Evidence|February 25, 2025
Haploidentical Bone Marrow Transplantation for Sickle Cell DiseaseAdetola A Kassim, Mark C Walters, Mary Eapen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 15, 2017
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic SyndromesAaron T Gerds, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood Advances|November 7, 2018
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemiaSaurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, et al.
JAMA Oncology|May 6, 2021
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell TransplantMichael Scordo, Trent P Wang, Kwang W Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>Mark J Levis, Mehdi Hamadani, Brent Logan, et al.
Leukemia|June 6, 2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Bone Marrow Transplantation|February 1, 2018
Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantationLucie M Turcotte, Tao Wang, Michael T Hemmer, et al.
Haematologica|April 21, 2022
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysisMatthew Mei, Raju Pillai, Soyoung Kim, et al.
Pageof 11